HBM Partners
Priyanka Belawat serves as a Partner at HBM Partners since February 2007, focusing on investments in oncology and specialty pharmaceuticals. Notable recent board memberships include IO Biotech, Bioatla, iTeos, Neurelis Inc, and Adrenomed, showcasing expertise in drug development and epilepsy treatment. Additionally, Priyanka held a board member position at South Pole from June 2022 to October 2023 and has previously participated on the boards of Bioatla and iTeos Therapeutics. Educational background includes a Doctorate in Genetics and Molecular Biology from the University of Zurich, completed in 2006.
This person is not in any teams
HBM Partners
HBM Partners was founded in 2001 with the goal to invest in private and public emerging biopharma and other healthcare-related companies. HBM Partners has a team of experienced professionals to source, analyse and engage in investments in biopharma, medical devices and diagnostics industries. HBM Partners has a track-record of over 100 investments that resulted so far in significant value creation by more than 60 trade sales and IPOs since inception. HBM Partners is regulated by FINMA and advises SIX listed HBM Healthcare Investments and further specialised public and private equity investment products.